JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLC

被引：16

作者：

Jerusalem, Guy ^{[1
,2
]}

Chen, Franklin ^{[3
]}

Spigel, David ^{[4
]}

Iannotti, Nicholas ^{[5
]}

Mcclay, Edward ^{[6
]}

Redfern, Charles ^{[7
]}

Bennouna, Jaafar ^{[8
]}

Taylor, Matthew ^{[9
]}

Kaufman, Howard ^{[10
]}

Kelly, Karen ^{[11
]}

Chand, Vikram ^{[12
]}

Von Heydebreck, Anja ^{[13
]}

Verschraegen, Claire ^{[14
]}

机构：

[1] CHU Sart Tilman Liege, Liege, Belgium

[2] Univ Liege, Liege, Belgium

[3] Novant Hlth Oncol Specialists, Winston Salem, NC USA

[4] Sarah Cannon Res Inst, North Nashville, TN USA

[5] Hematol Oncol Associates Treasure Coast, Port St Lucie, FL USA

[6] Calif Canc Associates Res & Excellence, Encinitas, CA USA

[7] Sharp Healthcare, San Diego, CA USA

[8] Ico Rene Gauducheau Recruiting, St Herblain, France

[9] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[10] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[11] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA

[12] Emd Serono Inc, Billerica, MA USA

[13] Merck KGaA, Darmstadt, Germany

[14] Univ Vermont, Ctr Canc, Burlington, VT USA

来源：

关键词：

1L NSCLC; phase i; avelumab; PD-L1;

D O I：

10.1016/j.jtho.2016.11.240

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA03.03

引用

页码：S252 / S252

页数：1